These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12472171)

  • 1. Penetrating the blind in a study of an SSRI.
    Piasecki MP; Antonuccio DO; Steinagel GM; Kohlenberg BS; Kapadar K
    J Behav Ther Exp Psychiatry; 2002 Jun; 33(2):67-71. PubMed ID: 12472171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness study of a year follow-up of selective serotonin reuptake inhibitor (SSRI) and augmentor combination compared with SSRI and placebo.
    Tome MB; Isaac MT
    Int Clin Psychopharmacol; 1998 Jul; 13(4):175-82. PubMed ID: 9727728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults.
    Weiss M; Hechtman L;
    J Clin Psychiatry; 2006 Apr; 67(4):611-9. PubMed ID: 16669726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline.
    Ball SG; Kuhn A; Wall D; Shekhar A; Goddard AW
    J Clin Psychiatry; 2005 Jan; 66(1):94-9. PubMed ID: 15669894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective serotonin reuptake inhibitors, fluoxetine and paroxetine, attenuate the expression of the established behavioral sensitization induced by methamphetamine.
    Kaneko Y; Kashiwa A; Ito T; Ishii S; Umino A; Nishikawa T
    Neuropsychopharmacology; 2007 Mar; 32(3):658-64. PubMed ID: 16738540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man.
    Schmitt JA; Ramaekers JG; Kruizinga MJ; van Boxtel MP; Vuurman EF; Riedel WJ
    J Psychopharmacol; 2002 Sep; 16(3):207-14. PubMed ID: 12236626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder.
    Seedat S; Stein MB
    J Clin Psychiatry; 2004 Feb; 65(2):244-8. PubMed ID: 15003080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.
    Richard IH; McDermott MP; Kurlan R; Lyness JM; Como PG; Pearson N; Factor SA; Juncos J; Serrano Ramos C; Brodsky M; Manning C; Marsh L; Shulman L; Fernandez HH; Black KJ; Panisset M; Christine CW; Jiang W; Singer C; Horn S; Pfeiffer R; Rottenberg D; Slevin J; Elmer L; Press D; Hyson HC; McDonald W;
    Neurology; 2012 Apr; 78(16):1229-36. PubMed ID: 22496199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression.
    Verkes RJ; Van der Mast RC; Hengeveld MW; Tuyl JP; Zwinderman AH; Van Kempen GM
    Am J Psychiatry; 1998 Apr; 155(4):543-7. PubMed ID: 9546002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study.
    Montgomery SA; Kennedy SH; Burrows GD; Lejoyeux M; Hindmarch I
    Int Clin Psychopharmacol; 2004 Sep; 19(5):271-80. PubMed ID: 15289700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression.
    Zanardi R; Franchini L; Gasperini M; Perez J; Smeraldi E
    Am J Psychiatry; 1996 Dec; 153(12):1631-3. PubMed ID: 8942464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An exploratory study: the use of paroxetine for methamphetamine craving.
    Piasecki MP; Steinagel GM; Thienhaus OJ; Kohlenberg BS
    J Psychoactive Drugs; 2002; 34(3):301-4. PubMed ID: 12422941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Childhood abuse and treatment response in patients with irritable bowel syndrome: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release.
    Han C; Masand PS; Krulewicz S; Peindl K; Mannelli P; Varia IM; Pae CU; Patkar AA
    J Clin Pharm Ther; 2009 Feb; 34(1):79-88. PubMed ID: 19125906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial.
    Stearns V; Beebe KL; Iyengar M; Dube E
    JAMA; 2003 Jun; 289(21):2827-34. PubMed ID: 12783913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial.
    Deakin JB; Rahman S; Nestor PJ; Hodges JR; Sahakian BJ
    Psychopharmacology (Berl); 2004 Apr; 172(4):400-8. PubMed ID: 14666399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder.
    Kasper S; Olivieri L; Di Loreto G; Dionisio P
    Curr Med Res Opin; 2005 Aug; 21(8):1139-46. PubMed ID: 16083521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.
    Baldwin DS; Cooper JA; Huusom AK; Hindmarch I
    Int Clin Psychopharmacol; 2006 May; 21(3):159-69. PubMed ID: 16528138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of mirtazapine as add-on to paroxetine
    Xiao L; Zhu X; Gillespie A; Feng Y; Zhou J; Chen X; Gao Y; Wang X; Ma X; Gao C; Xie Y; Pan X; Bai Y; Xu X; Wang G; Chen R
    Psychol Med; 2021 May; 51(7):1166-1174. PubMed ID: 31931894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risperidone and paroxetine given singly and in combination for bipolar depression.
    Shelton RC; Stahl SM
    J Clin Psychiatry; 2004 Dec; 65(12):1715-9. PubMed ID: 15641878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.